Scientific Project Manager

Camille Brochier

Oncology, Immunology & Rare blood disorders

“At Institut Roche, we work at the crossroad of industry and academia. We are lucky to work everyday with the best international scientists, and foster meaningful research collaborations that will directly benefit human health.”

Your role at Institut Roche and brief presentation of your professional background:

I joined Institut Roche in 2018 as a Scientific Project Manager. My role is to work withRoche’s R&D teams and find the external expertise and resources that will accelerate scientific discoveries and bring new treatments to patients.
In other words, I am involved in the scouting, set-up and long-term management of collaborative translational research programs between our R&D teams and academia. I am also lucky to be a thesis advisor and help train the next generation of research scientists.
A molecular neurobiologist by training (Ph.D. from Paris-Saclay University, France), I also hold a Master in Biopharmaceutical Management (ESCP Europe business school). I have worked over 10 years in academia, first as a postdoctoral researcher at the Burke Neurological Institute (White Plains, NY) and then as Junior Faculty at Weill Cornell Medicine (New York, NY).

My Focus at Institut Roche:

My efforts at Institut Roche are directed towards the fields of oncology, immunology and rare blood disorders

  1. Mutala, L. B., et al. (2021). “The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.” Cancers (Basel) 13(2).
  2. Brochier, C*., et al. (2015). “Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration.” Proc Natl Acad Sci U S A 112(49): 15220-15225.
  3. Segretti, M. C., et al. (2015). “Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function.” ACS Med Chem Lett 6(11): 1156-1161.
  4. Aleyasin, H., et al. (2015). “Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.” Antioxid Redox Signal 22(2): 121-134.
  5. Brochier, C., et al. (2013). “Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.” J Neurosci 33(20): 8621-8632.
  6. Brochier, C*. and B. Langley (2013). “Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases.” Neurotherapeutics 10(4): 817-830.
  7. Butler, K. V., et al. (2010). “Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.” J Am Chem Soc 132(31): 10842-10846.
  8. Langley B, Brochier C, Rivieccio MA. (2009).”Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke”. Stroke 40(8):2899-905.
  9. Rivieccio, M. A., Brochier C et al. (2009). “HDAC6 is a target for protection and regeneration following injury in the nervous system.” Proc Natl Acad Sci U S A 106(46): 19599-19604.
  10. Brochier, C., et al. (2008). “Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models.” Physiol Genomics 33(2): 170-179.
  11. de Chaldée M, Brochier C et al. (2006). “ Capucin: a novel striatal marker down-regulated in rodent models of Huntington disease”. Genomics 87(2):200
    *corresponding author
More publications